MCID: PNC034
MIFTS: 46

Pancreas Disease

Categories: Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreas Disease

Summaries for Pancreas Disease

Disease Ontology : 12 An endocrine system disease that is located in the pancreas.

MalaCards based summary : Pancreas Disease, also known as pancreatic diseases, is related to non-alcoholic fatty liver disease and pancreatic cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Pancreas Disease is MIR21 (MicroRNA 21), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Esomeprazole and Propofol have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and testes.

Related Diseases for Pancreas Disease

Diseases related to Pancreas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic fatty liver disease 31.4 MIR34A MIR31 MIR30A MIR21 MIR200C MIR17
2 pancreatic cancer 31.1 MIR483 MIR34A MIR30A MIR221 MIR21 MIR200C
3 pancreatic adenocarcinoma 30.4 MIR221 MIR21 MIR196A1 MIR155 INS
4 alcohol use disorder 30.3 MIR199A1 H2AC18 CCR6
5 endocrine pancreas disease 12.2
6 pancreas, annular 11.0
7 pancreatic agenesis 11.0
8 cystadenocarcinoma 10.9 SERPINA3 MIR30A MIR199A1
9 bacterial infectious disease 10.9 SERPINA3 MIR155 H2AC18 CCR6
10 serous cystadenocarcinoma 10.9 MIR30A MIR199A1 MIR10B H2AC18
11 contractures, pterygia, and variable skeletal fusions syndrome 1a 10.9 SERPINA3 MIR199A1 MIR196A1 MIR17 INS H2AC18
12 gastrointestinal system benign neoplasm 10.9 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
13 retinal vascular disease 10.8 MIR30A MIR21 MIR199A1 MIR126 INS H2AC18
14 vascular disease 10.8 MIR221 MIR21 MIR199A1 MIR126 MIR125A INS
15 heart conduction disease 10.8 MIR21 MIR199A1 MIR142 MIR126 INS H2AC18
16 ovary epithelial cancer 10.8 SERPINA3 MIR483 MIR30A MIR21 MIR199A1 MIR196A1
17 malignant ovarian surface epithelial-stromal neoplasm 10.8 SERPINA3 MIR483 MIR30A MIR21 MIR199A1 MIR196A1
18 polymyositis 10.8 MIR30A MIR221 MIR21 MIR155
19 ovarian serous carcinoma 10.8 MIR21 MIR200C MIR199A1 MIR125A MIR10B
20 mature b-cell neoplasm 10.8 MIR199A1 MIR196A1 MIR17 MIR155 MIR142 H2AC18
21 intestinal benign neoplasm 10.8 SERPINA3 MIR31 MIR21 MIR199A1 MIR17 MIR142
22 lipid storage disease 10.8 SERPINA3 MIR199A1 INS H2AC18 CCR6
23 rectum cancer 10.8 MIR483 MIR31 MIR21 MIR196A1 MIR17 MIR125A
24 primary bacterial infectious disease 10.8 SERPINA3 MIR21 MIR155 MIR125A H2AC18 CCR6
25 skeletal muscle cancer 10.8 SERPINA3 MIR486-1 MIR199A1 MIR196A1 H2AC18
26 autoimmune disease of endocrine system 10.8 MIR125A INS H2AC18 CCR6
27 lymphatic system cancer 10.8 SERPINA3 MIR17 MIR142 MIR126 H2AC18 CCR6
28 muscle cancer 10.8 SERPINA3 MIR486-1 MIR199A1 MIR196A1 H2AC18
29 substance abuse 10.8 SERPINA3 MIR199A1 INS H2AC18 CCR6
30 lymphatic system disease 10.8 SERPINA3 MIR483 MIR17 MIR125A H2AC18 CCR6
31 parasitic helminthiasis infectious disease 10.8 SERPINA3 MIR21 H2AC18 CCR6
32 collagen disease 10.8 SERPINA3 MIR30A MIR21 MIR142 H2AC18 CCR6
33 miyoshi muscular dystrophy 1 10.8 MIR34A MIR30A MIR221 MIR21 MIR155
34 uveal disease 10.8 SERPINA3 MIR199A1 MIR142 H2AC18 CCR6
35 bone resorption disease 10.8 MIR199A1 MIR142 INS H2AC18 CCR6
36 bone remodeling disease 10.8 MIR199A1 MIR142 INS H2AC18 CCR6
37 muscle tissue disease 10.8 SERPINA3 MIR221 MIR199A1 MIR196A1 MIR142 INS
38 ocular cancer 10.8 MIR483 MIR199A1 MIR196A1 MIR17 MIR142 MIR125A
39 connective tissue cancer 10.8 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
40 x-linked recessive disease 10.8 SERPINA3 MIR196A1 MIR142 H2AC18 CCR6
41 inherited metabolic disorder 10.8 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
42 laryngeal disease 10.8 MIR486-1 MIR34A MIR21 MIR196A1 MIR17 MIR142
43 testicular disease 10.8 SERPINA3 MIR199A1 H2AC18 CCR6
44 ovarian cystadenocarcinoma 10.8 SERPINA3 MIR483 MIR30A MIR200C MIR196A1 MIR17
45 tongue disease 10.8 MIR486-1 MIR483 MIR30A MIR21 MIR199A1 MIR196A1
46 aortic valve disease 2 10.8 SERPINA3 MIR486-1 MIR34A MIR21 MIR199A1 MIR17
47 peripheral nervous system neoplasm 10.8 SERPINA3 MIR486-1 MIR34A MIR199A1 MIR196A1 MIR17
48 thyroid gland papillary carcinoma 10.8 MIR486-1 MIR30A MIR221 MIR199A1 MIR17 MIR125A
49 gallbladder disease 10.8 SERPINA3 MIR199A1 MIR17 MIR142 INS
50 autonomic nervous system neoplasm 10.8 SERPINA3 MIR34A MIR199A1 MIR196A1 MIR17 MIR142

Graphical network of the top 20 diseases related to Pancreas Disease:



Diseases related to Pancreas Disease

Symptoms & Phenotypes for Pancreas Disease

UMLS symptoms related to Pancreas Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom

Drugs & Therapeutics for Pancreas Disease

Drugs for Pancreas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Remifentanil Approved Phase 4 132875-61-7 60815
5
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
6
Acetaminophen Approved Phase 4 103-90-2 1983
7 Rebamipide Investigational Phase 4 90098-04-7
8 Gastrointestinal Agents Phase 4
9 Proton Pump Inhibitors Phase 4
10 Anti-Ulcer Agents Phase 4
11 Antacids Phase 4
12 Hypnotics and Sedatives Phase 4
13 Analgesics, Non-Narcotic Phase 4
14 Antipyretics Phase 4
15
Pancrelipase Approved, Investigational Phase 3 53608-75-6
16
Scopolamine Approved, Investigational Phase 3 51-34-3, 6533-68-2 5184
17
Papaverine Approved, Investigational Phase 3 58-74-2, 61-25-6 4680
18
Ivacaftor Approved Phase 3 873054-44-5 16220172
19
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
20
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
21
Cefotaxime Approved Phase 3 63527-52-6 456256 5742673
22
Piperacillin Approved Phase 3 66258-76-2 43672
23
Tazobactam Approved Phase 3 89786-04-9 123630
24
Cefoxitin Approved Phase 3 35607-66-0 441199
25
Sevoflurane Approved, Vet_approved Phase 2, Phase 3 28523-86-6 5206
26
Ropivacaine Approved Phase 2, Phase 3 84057-95-4 71273 175805
27
Sufentanil Approved, Investigational Phase 2, Phase 3 56030-54-7 41693
28
Bupivacaine Approved, Investigational Phase 2, Phase 3 38396-39-3, 2180-92-9 2474
29
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
30
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
31
Methionine Approved, Nutraceutical Phase 3 63-68-3 6137
32
Beta carotene Approved, Nutraceutical Phase 3 7235-40-7
33 Tocotrienol Investigational Phase 3 6829-55-6
34 pancreatin Phase 3
35 Liver Extracts Phase 3
36 Antioxidants Phase 3
37 Neurotransmitter Agents Phase 3
38 Phosphodiesterase Inhibitors Phase 3
39 Antiemetics Phase 3
40 Vasodilator Agents Phase 3
41 Autonomic Agents Phase 3
42 Muscarinic Antagonists Phase 3
43 Butylscopolammonium Bromide Phase 3
44 Mydriatics Phase 3
45 Cholinergic Agents Phase 3
46 Bromides Phase 3
47 Cholinergic Antagonists Phase 3
48 Parasympatholytics Phase 3
49 Drotaverin Phase 3
50 Vitamins Phase 3

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Prevention for Surgical Site Infection After Pancreatic Resection Unknown status NCT00661648 Phase 4
2 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
3 Alfentanil vs Remifentanil in Patient-controlled Sedation During ERCP.A Randomized Double-blind Study Completed NCT01350037 Phase 4 alfentanil;remifentanil
4 Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
5 A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
6 Role of Scheduled Intravenous Acetaminophen for Postoperative Pain Management in an Enhanced Recovery After Surgery (ERAS) Population: A Prospective, Randomized, Double-Blind and Placebo-Controlled Clinical Trial Active, not recruiting NCT03198871 Phase 4 Acetaminophen Injectable Product;Sodium Chloride 0.9%, Intravenous
7 A Placebo Controlled, Double-Blind, Parallel, Multicenter Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers Completed NCT01087801 Phase 3 ChiRhoStim;Placebo
8 Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial Completed NCT00731198 Phase 3 Drotaverine hydrochloride;Hyoscine-N-butylbromide
9 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation Completed NCT00909532 Phase 3 Ivacaftor;Placebo
10 A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 to 11 Years With Cystic Fibrosis and the G551D Mutation Completed NCT00909727 Phase 3 Ivacaftor;Placebo
11 Phase III Study of Efficacy of Remote Ischemic Preconditioning in Improving Outcomes in Organ Transplantation Completed NCT00975702 Phase 3
12 Effect of Antioxidant Supplementation on Pain, Antioxidant Profile and Oxidative Stress in Patients With Chronic Pancreatitis Completed NCT00319358 Phase 3
13 A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy Recruiting NCT03269994 Phase 3 Cefoxitin;Piperacillin-tazobactam
14 Saline Hypertonic in Preschoolers With Cystic Fibrosis and Lung Structure as Measured by Computed Tomography (CT) Recruiting NCT02950883 Phase 2, Phase 3 Active Treatment Group 7% Hypertonic Saline;Control Group 0.9% Isotonic Saline
15 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
16 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel 125 mg/m2;gemcitabine 1000 mg/m2;gemcitabine 1000 mg/m2
17 The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery Not yet recruiting NCT04021264 Phase 2, Phase 3 Ropivacaine-Sufentanil;Dextrose 5
18 A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme® Unknown status NCT02722122 Phase 2 AIR DNase™
19 A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the ∆F508-CFTR Gene Mutation Completed NCT00865904 Phase 2 VX-809;Placebo
20 A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
21 An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
22 A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas Completed NCT01088815 Phase 2 Gemcitabine, nab-Paclitaxel, GDC-0449
23 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects With Genotype G551D Completed NCT00457821 Phase 2 Ivacaftor 25 mg/75 mg;Ivacaftor 75 mg/150 mg;Ivacaftor 150 mg or 250 mg;Placebo
24 A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer Recruiting NCT03535727 Phase 1, Phase 2 Nab-paclitaxel;Gemcitabine;Capecitabine;Cisplatin;Irinotecan;Nab-paclitaxel;Gemcitabine;Capecitabine;Cisplatin;Irinotecan
25 Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II Recruiting NCT03717298 Phase 2
26 Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma Recruiting NCT03077685 Phase 2 NanoPac®
27 A Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms Recruiting NCT03188991 Phase 2 NanoPac®
28 A Single-arm Phase II Trial of Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy Active, not recruiting NCT03410914 Phase 2
29 Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED) Terminated NCT00040131 Phase 2 IL-10
30 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Terminated NCT00953706 Phase 2 Ivacaftor;Placebo
31 A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma Terminated NCT00496223 Phase 1, Phase 2 Sunitinib;Dacarbazine
32 Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer Terminated NCT01555489 Phase 2 Ascorbic Acid
33 Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma. Terminated NCT01431794 Phase 1, Phase 2 LDE225-600mg;Gemcitabine;nab-paclitaxel;LDE225-400mg;LDE225-800mg
34 A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors. Terminated NCT01215578 Phase 2 Sutent
35 A Randomised, Double-blind, Placebo-controlled Dose-escalation Phase I Study to Evaluate the Safety and Tolerability of Inhaled Aerosolised OligoG CF-5/20 (G-block Oligosaccharide Derived From Alginate Polysaccharide) in Healthy Volunteers Completed NCT00970346 Phase 1 OligoG CF-5/20
36 89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g Completed NCT01832116 Phase 1 89Zr-MMOT0530A
37 Remote Telemonitoring to Improve Prehabilitation and Surgical Outcomes of Patients Undergoing Pancreatic Resection Recruiting NCT03706963 Phase 1
38 A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
39 RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis Terminated NCT00620919 Phase 1 RG1068 (Synthetic Human Secretin)
40 Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Unknown status NCT01427712
41 Zhujiang Hospital of the Southern Medical University Unknown status NCT03074708
42 Indications and Outcomes of Gastrointestinal Endoscopic Ultrasound in Tanta-Egypt: Initial Experience. Unknown status NCT03267355
43 A Network on the Quality of ERCP, on the Organization of the Endoscopic Units and on the Training of the Endoscopists in Italy Unknown status NCT02971579
44 Effectiveness of Metal Protheses Covered in "Diabolo" in Treatment of Necrosis of Origin Pancreatic: Trial "DIABOLOPIG" Unknown status NCT02739074
45 Cell-free DNA Promoter Hypermethylation in Plasma From Patients With Pancreatic Adenocarcinoma, Compared to Patients With Pancreatitis and Pancreatitis and Patients Screened for, But Not Having Pancreatic Adenocarcinoma." Unknown status NCT02079363
46 Comparative Study Between Minimally Invasive Pancreatico-duodenectomy and Open Pancreatico-duodenectomy for Periampullary Tumors Unknown status NCT02807701
47 The Natural History of Chronic Pancreatitis: A Multicenter Study Unknown status NCT03324698
48 Benefit of Tight Glycemic Control in Surgical Patients: Prospective Randomized Clinical Trial Unknown status NCT00735228
49 Endoscopic Retrograde Cholangiopancreatography, Endoscopic Ultrasound and Interventional Endoscopy in Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Unknown status NCT01438385
50 Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During Endoscopic Retrograde Cholangiopancreatography: a Prospective Randomized Controlled Study Unknown status NCT01900938 Midazolam;Propofol

Search NIH Clinical Center for Pancreas Disease

Genetic Tests for Pancreas Disease

Anatomical Context for Pancreas Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreas Disease:

19
Pancreas

MalaCards organs/tissues related to Pancreas Disease:

40
Pancreas, Liver, Testes, Heart, Bone, Thyroid, Kidney

Publications for Pancreas Disease

Articles related to Pancreas Disease:

(show top 50) (show all 2487)
# Title Authors PMID Year
1
Performance of deep learning for differentiating pancreatic diseases on contrast-enhanced magnetic resonance imaging: A preliminary study. 61
31375430 2020
2
Full Robotic Distal Pancreatectomy: Safety and Feasibility Analysis of a Multicenter Cohort of 236 Patients. 61
31394981 2020
3
Metabolome of pancreatic juice delineates distinct clinical profiles of pancreatic cancer and reveals a link between glucose metabolism and PD-1+ cells. 61
32019781 2020
4
Pancreatic and duodenal homeobox-1 in pancreatic ductal adenocarcinoma and diabetes mellitus. 61
31904730 2020
5
3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. 61
31947550 2020
6
Life-threatening duodenal perforation complicating endoscopic retrograde cholangiopanceatography: A case series. 61
31978721 2020
7
Association of pancreatic fat content with type II diabetes mellitus. 61
31711639 2020
8
Effects of Immunonutrition on Comprehensive Complication Index in Patients Undergoing Pancreatoduodenectomy. 61
31991566 2020
9
Ancillary Techniques in Cytologic Specimens Obtained from Solid Lesions of the Pancreas: A Review. 61
30970350 2020
10
Pancreatic stellate cell-potentiated insulin secretion from Min6 cells is independent of interleukin 6-mediated pathway. 61
31452250 2020
11
Response of the Salmon Heart Transcriptome to Pancreas Disease: Differences Between High- and Low-Ranking Families for Resistance. 61
31964968 2020
12
Lipocalin-2 expression and function in pancreatic diseases. 61
31932215 2020
13
Microbiota in pancreatic health and disease: the next frontier in microbiome research. 61
31811279 2020
14
How Does Ultrasound Manage Pancreatic Diseases? Ultrasound Findings and Scanning Maneuvers. 61
31009959 2020
15
Nonalcoholic Fatty Pancreas Disease: Clinical Consequences. 61
31865317 2020
16
E-Cadherin: An Enigma in Pancreatic Diseases. 61
31678202 2020
17
Histopathology and Feline Pancreatic Lipase Immunoreactivity in Inflammatory, Hyperplastic and Neoplastic Pancreatic Diseases in Cats. 61
31955805 2020
18
Comparison of 22G standard and Franseen needles in endoscopic ultrasound-guided fine-needle aspiration for diagnosing pancreatic mass lesions: Study protocol for a controlled trial. 61
31888733 2019
19
Benign pancreatic hyperenzymemia-Gullo's syndrome: focus on this clinical challenge. A monocentric retrospective study. 61
31638356 2019
20
Single-session esophagogastroduodenoscopy and endoscopic ultrasound using a forward-viewing radial scan ultrasonic endoscope. 61
31852458 2019
21
[Diagnostic value and patient compliance of a pancreas-oriented multidisciplinary clinic: a retrospective analysis from a Chinese pancreatic disease center]. 61
31826595 2019
22
Serum levels of advanced glycation end products and their receptors sRAGE and Galectin-3 in chronic pancreatitis. 61
31870801 2019
23
Leukocytosis after distal pancreatectomy and splenectomy as a marker of major complication. 61
31848020 2019
24
The role of interleukin-18 in pancreatitis and pancreatic cancer. 61
31753718 2019
25
Long non-coding RNA HULC as a diagnostic and prognostic marker of pancreatic cancer. 61
31857775 2019
26
Pancreatic Ductal Adenocarcinoma in Remnant Pancreas after Pancreaticoduodenectomy for Acinar Cell Carcinoma: A Case Report. 61
31061255 2019
27
Complete duodenal obstruction induced by groove pancreatitis: A case report. 61
31832415 2019
28
Prevalence Rate and Predictive Factors of Pancreatic Diseases in Cases with Pancreatic Duct Dilatation: A Cross-sectional Study of a Large, Healthy Japanese Population. 61
31813913 2019
29
Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. 61
31688587 2019
30
A modified in vitro tool for isolation and characterization of rat quiescent islet stellate cells. 61
31505166 2019
31
Human pancreatic afferent and efferent nerves: mapping and 3-D illustration of exocrine, endocrine, and adipose innervation. 61
31509431 2019
32
Combined use of Serum miR-499a-5p and CA199 Increases the Diagnostic Sensitivity of Pancreatic Cancer. 61
31710444 2019
33
Predictive Value of Localized Stenosis of the Main Pancreatic Duct for Early Detection of Pancreatic Cancer. 61
31744269 2019
34
Significance of IL28RA in diagnosis of early pancreatic cancer and its regulation to pancreatic cancer cells by JAK/STAT signaling pathway - effects of IL28RA on pancreatic cancer. 61
31799654 2019
35
Estimating risk factors for the daily risk of developing clinical cardiomyopathy syndrome (CMS) on a fishgroup level. 61
31790932 2019
36
The hollow adrenal gland sign: a newly described enhancing pattern of the adrenal gland on dual-phase contrast-enhanced CT for predicting the prognosis of patients with septic shock. 61
30937586 2019
37
Early oral vs parenteral nutrition in acute pancreatitis: a retrospective analysis of clinical outcomes and hospital costs from a tertiary care referral center. 61
31620978 2019
38
Pancreas divisum inversus. 61
31576611 2019
39
Nonalcoholic Fatty Pancreas Disease. 61
31535735 2019
40
Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings. 61
31660327 2019
41
Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer. 61
31582345 2019
42
Aquaporins Involvement in Pancreas Physiology and in Pancreatic Diseases. 61
31614661 2019
43
Laparoscopic surgery in pancreatic diseases: Pushing the boundaries. 61
31719728 2019
44
Non-occlusive Mesenteric Ischemia as a Fatal Complication in Acute Pancreatitis: A Case Series. 61
31529415 2019
45
Safety and efficacy of enhanced recovery after surgery in elderly patients after therapeutic endoscopic retrograde cholangiopancreatography. 61
31534569 2019
46
A semicentennial of pancreatic pathology: the genetic revolution is here, but don't throw the baby out with the bath water! 61
31521627 2019
47
Role of Fibre in Nutritional Management of Pancreatic Diseases. 61
31540004 2019
48
Normal T1 relaxometry and extracellular volume of the pancreas in subjects with no pancreas disease: correlation with age and gender. 61
31139885 2019
49
Non-alcoholic fatty pancreas disease - practices for clinicians. 61
30901317 2019
50
Management of pancreatic exocrine insufficiency. 61
31219829 2019

Variations for Pancreas Disease

Expression for Pancreas Disease

Search GEO for disease gene expression data for Pancreas Disease.

Pathways for Pancreas Disease

Pathways related to Pancreas Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR483 MIR34A MIR31 MIR30A MIR221 MIR21

GO Terms for Pancreas Disease

Cellular components related to Pancreas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.47 SERPINA3 MIR486-1 MIR31 MIR30A MIR221 MIR21

Biological processes related to Pancreas Disease according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 MIR34A MIR30A MIR21 MIR155 MIR125A INS
2 negative regulation of gene expression GO:0010629 9.93 MIR21 MIR17 MIR155 MIR125A
3 positive regulation of protein kinase B signaling GO:0051897 9.88 MIR221 MIR21 MIR199A1 MIR126 INS
4 cellular response to hypoxia GO:0071456 9.86 MIR34A MIR17 MIR155 MIR126
5 negative regulation of inflammatory response GO:0050728 9.85 MIR31 MIR221 MIR155 MIR126
6 positive regulation of angiogenesis GO:0045766 9.83 MIR31 MIR30A MIR21 MIR199A1 MIR126
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 MIR21 MIR126 INS
8 positive regulation of inflammatory response GO:0050729 9.8 MIR21 MIR155 MIR126
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.76 MIR221 MIR21 MIR17
10 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.74 MIR31 MIR126 MIR10B
11 negative regulation of sprouting angiogenesis GO:1903671 9.71 MIR34A MIR221 MIR17
12 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.67 MIR199A1 MIR17 MIR155
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.67 MIR31 MIR30A MIR221 MIR126
14 positive regulation of endothelial cell differentiation GO:0045603 9.65 MIR21 MIR200C
15 negative regulation of innate immune response GO:0045824 9.65 MIR21 MIR155
16 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.64 MIR21 INS
17 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.64 MIR17 MIR155
18 positive regulation of connective tissue replacement GO:1905205 9.63 MIR34A MIR199A1 MIR155
19 positive regulation of microglial cell activation GO:1903980 9.62 MIR155 MIR142
20 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.62 MIR483 MIR221 MIR196A1 MIR155
21 positive regulation of metalloendopeptidase activity GO:1904685 9.61 MIR21 MIR17
22 negative regulation by host of viral genome replication GO:0044828 9.61 MIR221 MIR155
23 negative regulation of regulatory T cell differentiation GO:0045590 9.6 MIR21 MIR155
24 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.59 MIR21 MIR17
25 negative regulation of cell adhesion molecule production GO:0060354 9.58 MIR221 MIR155
26 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR199A1 MIR17 MIR155
27 miRNA mediated inhibition of translation GO:0035278 9.56 MIR483 MIR31 MIR30A MIR221 MIR21 MIR200C
28 negative regulation of vascular wound healing GO:0061044 9.52 MIR34A MIR155
29 gene silencing by miRNA GO:0035195 9.47 MIR483 MIR34A MIR31 MIR30A MIR221 MIR21
30 positive regulation of sprouting angiogenesis GO:1903672 9.46 MIR31 MIR155 MIR126 MIR125A
31 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.43 MIR31 MIR221 MIR155

Molecular functions related to Pancreas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR483 MIR34A MIR31 MIR30A MIR221 MIR21

Sources for Pancreas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....